ChinaDaily Briefs

Daily Brief China: REPT BATTERO Energy, Akeso Biopharma Inc, Chindata Group, CPMC Holdings, Topchoice Medical and more

In today’s briefing:

  • Rept Battero IPO: The Bear Case
  • [Blue Lotus Sector Update]: Solid Companies Starting to Rise from the Ashes
  • (Mostly) Asia-Pac Weekly Risk Arb Wrap: Perpetual, Weiqiao Textile,Tokyo Rakutenchi,Toyo, Chindata
  • Weekly Deals Digest (10 Dec) – CPMC, Weiqiao, Benefit One, Tokyo Rakutenchi, Eoflow, Rept Battero
  • China Healthcare Weekly (Dec.8) – Important Trends in Pharma, Big Discount Sale of Equity, Topchoice


Rept Battero IPO: The Bear Case

By Arun George

  • REPT BATTERO Energy (1998104D CH), a leading EV battery manufacturer, has launched an HKEx IPO to raise up to US$306 million. Pricing is on 14 December.   
  • In Rept Battero IPO: The Bull Case, we highlighted the key elements of the bull case. In this note, we outline the bear case.
  • The bear case rests on market share losses, high related party revenue, weak outlook, EV battery weak performance, FCF burn, high impairments and receivable financing. 

[Blue Lotus Sector Update]: Solid Companies Starting to Rise from the Ashes

By Eric Wen

  • China’s innovative drug sector remains a liquidity driven sector, as investible choices are limited, which include Akeso and BeiGene as our BUY ideas.
  • We also notice positive change in Innovent but opt to keep rating unchanged;
  • We upgrade BeiGene from SELL to BUY and maintain SELL on RemeGen, Innovent, JUNSHI and ZaiLab. We discontinued coverage on Legend Biotech.

(Mostly) Asia-Pac Weekly Risk Arb Wrap: Perpetual, Weiqiao Textile,Tokyo Rakutenchi,Toyo, Chindata

By David Blennerhassett


Weekly Deals Digest (10 Dec) – CPMC, Weiqiao, Benefit One, Tokyo Rakutenchi, Eoflow, Rept Battero

By Arun George


China Healthcare Weekly (Dec.8) – Important Trends in Pharma, Big Discount Sale of Equity, Topchoice

By Xinyao (Criss) Wang

  • We summarized some important opportunities and trends that we think would emerge in the pharmaceutical industry in the future.
  • Considering the current unfavorable financing situation of Biotech in the domestic primary market, we anticipate that there would be significant discounts in the sale of equity in the future.
  • Topchoice has not yet out of trouble. Most of its business diversification could end in failure. It is difficult to support high valuation only by one hospital and one region.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars